Psychedelic Research and Access in
Guatemala
Guatemala appears to have a restrictive controlled-substances regime for psychotropics, with legal access mainly channelled through state oversight and licensed medical use. Publicly available Ministry of Health material indicates that private and public health establishments, and certain professionals including anaesthesiologists, can apply for authorisation to handle and buy psychotropic and narcotic substances under set forms and procedures.
Data updated
Key Insights
A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inGuatemala.
- 1
The best-supported reading is a controlled, hospital-centred access model rather than a psychedelic-therapy ecosystem.
- 2
Ministry of Health procedures suggest that access to psychotropics is administratively possible, but only through authorisation and only for defined medical actors.
- 3
The absence of linked trials and events points to very limited visible psychedelic research infrastructure in the country at present.
- 4
Ketamine is the only psychedelic-adjacent medicine with clear clinical relevance in the public record, but that does not imply a mental-health access pathway.
- 5
Because public documentation on esketamine and classical psychedelics is sparse, the safest formulation is that these remain unverified or highly restricted rather than clearly available.
Research and Access Snapshot
Blossom currently tracks no country-linked psychedelic clinical trials for Guatemala, but the page does include 1 stakeholder.
Blossom has not linked country-level trial records yet. Treat this as a coverage gap, not proof that no local policy discussion, care, or informal activity exists.
- Active trials
- 0
- Total trials
- 0
- Stakeholders
- 1
- Events
- 0
None marked active
No linked trials
Linked organisations
No linked events
Top Compounds
Linked country trials do not show a leading compound yet.
Top Study Topics
Linked country trials do not show a leading study topic yet.
Medical Access
Guatemala maintains a restrictive national narcotics framework (Decreto No. 48-92) that broadly criminalizes controlled psychotropic substances and provides for tight state control; routinely this means licensed medical use is limited to recognized pharmaceuticals used in hospitals, while classical psychedelics (psilocybin, MDMA, DMT, 5-MeO-DMT, mescaline, 2C-X, ibogaine, ayahuasca) have no routine medical reimbursement or authorized outpatient medical programs and are only encountered in research/gray-zone settings or strictly prohibited. Ketamine is...
Regulatory Status
Guatemala's legal framework, including Decreto 48-92 (Ley Contra la Narcoactividad), supports tight state control over controlled substances, while Ministry of Health procedures show that psychotropics and narcotics can be authorised for specified health establishments and professionals. That said, I did not find a public source showing routine legal medical access for psilocybin, MDMA, DMT, 5-MeO-DMT, mescaline, 2C-X, ibogaine or ayahuasca, and any claim of outpatient psychedelic availability should be treated as unverified. Ketamine appears available in standard medical settings; I could not verify a public, reimbursed esketamine programme.
Country Details
- Region
- North America
- Last updated
- 4 May 2026
Country Report
Medical Only (Private)Medical Access
Guatemala maintains a restrictive national narcotics framework (Decreto No. 48-92) that broadly criminalizes controlled psychotropic substances and provides for tight state control; routinely this means licensed medical use is limited to recognized pharmaceuticals used in hospitals, while classical...
Open access guide →Pro Scorecard
Country Scorecard
Compare evidence, access, payment, delivery, local ecosystem, and review confidence for Guatemala.
Open scorecard →Psychedelic Stakeholders in Guatemala
Organisations, sponsors, clinics, and research groups connected to psychedelic science in Guatemala.